Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028
Study 1 of Essential3 program for ulixacaltamide in essential tremor (ET) on track for Q1 2025 interim analysis; NDA filing for ulixacaltamide expected in 2025
Enrollment in EMBOLD study of relutrigine cohort 2 is on track; targeting NDA filing in 2026
Vormatrigine ENERGY program advancing with read-outs of RADIANT in first half of 2025 and POWER1 by year-end 2025
UCB has exercised its option to license KCNT1 small molecule candidate for global development and commercialization
Cash and investments ~ $470 million at the end of 2024 support runway into 2028
BOSTON, Jan. 12, 2025 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS)…
